Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bidridistrogene Xeboparvovec · SRP-9003

Gene therapy (AAV vector) · Gene replacement · developed by Sarepta Therapeutics

Phase 3 Most advanced trial
SRPT Developer
1 Registered trials

What is Bidridistrogene Xeboparvovec?

Bidridistrogene xeboparvovec is an AAV-based gene therapy delivering a copy of the human SGCB gene, given as a single intravenous infusion. It is being studied in limb-girdle muscular dystrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SRP-9003
Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Neurology
Developer
Sarepta Therapeutics, Inc. (SRPT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
NM4FH5S2OW

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06246513 Phase 3 Limb-girdle Muscular Dystrophy Active not recruiting SRPT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Limb-girdle Muscular Dystrophy

More from Sarepta Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.

Follow SRPT, the company behind Bidridistrogene Xeboparvovec

See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SRPT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.